SCHEMBL4016785

SCHEMBL4016785

C[C@@H](N)c1cc(Cl)ccn1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
HTT P42858 1/20 0.44
KDM4C Q9H3R0 1/20 0.42
PNMT P11086 2/20 0.41
ADRB2 P07550 1/20 0.40
POLB P06746 1/20 0.39
NR4A2 P43354 3/20 0.37
SLC6A2 P23975 1/20 0.36
SLC6A3 Q01959 1/20 0.36
SOS2 Q07890 1/20 0.36
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4016781 1.00 LMNA (0.44) LMNATP53HTTKDM4CPNMT
SCHEMBL4016788 1.00 LMNA (0.44) LMNATP53HTTKDM4CPNMT
Hydrochloric Acid SCHEMBL14120737 0.98 LMNA (0.42) LMNATP53HTTKDM4CPNMT
Hydrochloric Acid SCHEMBL14157229 0.98 LMNA (0.42) LMNATP53HTTKDM4CPNMT
SCHEMBL908395 0.83 KDM4C (0.41) LMNATP53HTTKDM4CPNMT
SCHEMBL23343770 0.79 KDM4C (0.39) LMNATP53HTTKDM4CPNMT
SCHEMBL31059829 0.79 KDM4C (0.42) KDM4CPNMTPOLBNR4A2SOS2
SCHEMBL31059631 0.79 KDM4C (0.42) KDM4CPNMTPOLBNR4A2SOS2
SCHEMBL2088079 0.79 KDM4C (0.42) KDM4CPNMTPOLBNR4A2SOS2
SCHEMBL31059613 0.79 KDM4C (0.42) KDM4CPNMTPOLBNR4A2SOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3365334-B1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMA CO LTD (JP) 2024-07-17 EP disclosed
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-05-11 US disclosed
EP-1182199-B1 PROCESS FOR PREPARING AMIC ACID ESTERS IHARA CHEMICAL IND CO (JP) 2009-06-24 EP disclosed
US-6576765-B2 Process for preparing amic acid esters IHARA CHEMICAL INDUSTRY CO., LTD. (JP) 2003-06-10 US disclosed
US-20030032667-A1 PROCESS FOR PREPARING AMIC ACID ESTERS IHARA CHEMICAL INDUSTRY CO., LTD. (JP) 2003-02-13 US disclosed
EP-1182199-A1 PROCESS FOR PREPARING AMIC ACID ESTERS IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) 2002-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030032667-A1 PROCESS FOR PREPARING AMIC ACID ESTERS MCCC2, EMC1, GANC LMNA 1532/4885TP53 4197/4885HTT 4069/4885
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 LMNA 600/4885TP53 927/4885HTT 1760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.